search for


Management of Severe Fatigue Induced by Tyrosine Kinase Inhibitor in Radioiodine Refractory Thyroid Cancer
Int J Thyroidol 2018;11(2):75-77
Published online November 30, 2018;
© 2018 Korean Thyroid Association.

Byeong-Cheol Ahn

Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
Correspondence to: Byeong-Cheol Ahn, MD, PhD, Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea
Tel: 82-53-420-5583, Fax: 82-53-422-0864, E-mail:
Received October 15, 2018; Revised October 28, 2018; Accepted October 29, 2018.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tyrosine kinase inhibitor is known to prolong progression free survival in radioiodine refractory thyroid cancer patients. Fatigue/asthenia/malaise is one of most common adverse events by the tyrosine kinase inhibitor treatment, and management of the adverse event is important to keep the drug medication longer which is essential for the survival benefit. In the case report, a radioiodine refractory thyroid cancer patient receiving tyrosine kinase inhibitor experienced severe fatigue, and a pathologic fracture of right humerus occurred by slipping down which was tightly linked with the adverse event of the drug. The pathologic fracture was surgically well managed and the adverse event was well controlled by supportive managements combined with dose reduction of the tyrosine kinase inhibitor. The drug administration to the patient was kept more than 1 year without progression of the disease.
Keywords : Radioiodine refractory thyroid cancer, Tyrosine kinase inhibitor, Adverse events, Fatigue

November 2018, 11 (2)